Biotech | March 16, 2026
The biotechnology company will tap into Catalent’s expertise in induced pluripotent stem cells and advanced cell-therapy manufacturing
The endorsement follows overwhelming support for the share swap preceding the merger,
The move comes as the global biotech and biopharma CDMO market continues to surge, fueled by rising demand
The Japan Patent Office is considered one of the world's most rigorous and meticulous in its review process
The collaboration will leverage this clinical experience to inform NCEL-101 development, streamline regulatory pathways, and potentially accelerate timelines for achieving durable graft survival comparable to donor human islets
The agreement brings to market a method pioneered at CU Boulder that enables the reliable synthesis of long RNA strands
Germany will be the first launch market
Under the deal, Hims & Hers will offer patients access to FDA-approved versions of Ozempic and Wegovy at the same self-pay prices available through other telehealth platforms
Subscribe To Our Newsletter & Stay Updated
